Silverfin false false 30/04/2024 01/05/2023 30/04/2024 R Clarke 23/04/2024 D Yacoub 25/04/2023 25 April 2025 The principal activity of the company for the financial period ended 30 April 2024 is developing organoid intelligence applications. 14824935 2024-04-30 14824935 bus:Director1 2024-04-30 14824935 bus:Director2 2024-04-30 14824935 core:CurrentFinancialInstruments 2024-04-30 14824935 core:ShareCapital 2024-04-30 14824935 core:RetainedEarningsAccumulatedLosses 2024-04-30 14824935 bus:OrdinaryShareClass1 2024-04-30 14824935 2023-05-01 2024-04-30 14824935 bus:FilletedAccounts 2023-05-01 2024-04-30 14824935 bus:SmallEntities 2023-05-01 2024-04-30 14824935 bus:AuditExemptWithAccountantsReport 2023-05-01 2024-04-30 14824935 bus:PrivateLimitedCompanyLtd 2023-05-01 2024-04-30 14824935 bus:Director1 2023-05-01 2024-04-30 14824935 bus:Director2 2023-05-01 2024-04-30 14824935 bus:OrdinaryShareClass1 2023-05-01 2024-04-30 14824935 1 2023-05-01 2024-04-30 iso4217:GBP xbrli:pure xbrli:shares

Company No: 14824935 (England and Wales)

OMNIBIO LIMITED

Unaudited Financial Statements
For the financial period ended 30 April 2024
Pages for filing with the registrar

OMNIBIO LIMITED

Unaudited Financial Statements

For the financial period ended 30 April 2024

Contents

OMNIBIO LIMITED

COMPANY INFORMATION

For the financial period ended 30 April 2024
OMNIBIO LIMITED

COMPANY INFORMATION (continued)

For the financial period ended 30 April 2024
Directors R Clarke (Appointed 23 April 2024)
D Yacoub
Registered office 162a Broad Lane
Walsall
WS3 2TQ
United Kingdom
Company number 14824935 (England and Wales)
Accountant Kreston Reeves LLP
37 St Margarets Street
Canterbury
Kent
CT1 2TU

ACCOUNTANTS' REPORT TO THE BOARD OF DIRECTORS ON THE PREPARATION OF
THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF OMNIBIO LIMITED

For the financial period ended 30 April 2024

ACCOUNTANTS' REPORT TO THE BOARD OF DIRECTORS ON THE PREPARATION OF
THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF OMNIBIO LIMITED (continued)

For the financial period ended 30 April 2024

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Omnibio Limited for the financial period ended 30 April 2024 which comprise the Balance Sheet and the related notes 1 to 6 from the Company’s accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at www.icaew.com/regulation.

It is your duty to ensure that Omnibio Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of Omnibio Limited. You consider that Omnibio Limited is exempt from the statutory audit requirement for the financial period.

We have not been instructed to carry out an audit or a review of the financial statements of Omnibio Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

This report is made solely to the Board of Directors of Omnibio Limited, as a body, in accordance with the terms of our engagement letter dated 18 April 2025. Our work has been undertaken solely to prepare for your approval the financial statements of Omnibio Limited and state those matters that we have agreed to state to the Board of Directors of Omnibio Limited, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Omnibio Limited and its Board of Directors as a body for our work or for this report.

Kreston Reeves LLP
Chartered Accountants

37 St Margarets Street
Canterbury
Kent
CT1 2TU

25 April 2025

OMNIBIO LIMITED

BALANCE SHEET

As at 30 April 2024
OMNIBIO LIMITED

BALANCE SHEET (continued)

As at 30 April 2024
Note 2024
£
Current assets
Debtors 3 1,441
Cash at bank and in hand 340
1,781
Creditors: amounts falling due within one year 4 ( 17,974)
Net current liabilities (16,193)
Total assets less current liabilities (16,193)
Net liabilities ( 16,193)
Capital and reserves
Called-up share capital 5 2
Profit and loss account ( 16,195 )
Total shareholders' deficit ( 16,193)

For the financial period ending 30 April 2024 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The financial statements of Omnibio Limited (registered number: 14824935) were approved and authorised for issue by the Board of Directors on 25 April 2025. They were signed on its behalf by:

D Yacoub
Director
OMNIBIO LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial period ended 30 April 2024
OMNIBIO LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial period ended 30 April 2024
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial period, unless otherwise stated.

General information and basis of accounting

Omnibio Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is 162a Broad Lane, Walsall, WS3 2TQ, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Going concern

As noted in note 6, the company has raised £115,000 since the year end through a funding round. Furthermore the directors are committed to provide sufficient funding to enable the company to continue in operation for the foreseeable future. Therefore the accounts have been prepared on going concern basis

Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Ordinary share capital

The ordinary share capital of the Company is presented as equity.

2. Employees

2024
Number
Monthly average number of persons employed by the Company during the period, including directors 0

3. Debtors

2024
£
Other debtors 1,441

4. Creditors: amounts falling due within one year

2024
£
Other creditors 17,974

5. Called-up share capital

2024
£
Allotted, called-up and fully-paid
2 Ordinary shares of £ 1.00 each 2

During the period, 2 Ordinary shares of £1.00 each were issued at par.

6. Events after the Balance Sheet date

Since the year end, the company has raised £115,000 through a funding round.